A-443654

Cat. No.: 0225LY-0796

Appearance: Solid

Purity: ≥99%

Identity: Confirmed by NMR, HPLC, and LC-MS.

Size:

INQUIRY Datasheet MSDS

Add to basket

Product Overview

Description: A-443654 functions as a pan-Akt inhibitor that targets Akt1, Akt2, and Akt3 with uniform intracellular potency (Ki: 160 pM).

Synonym: 552325-16-3; (2s)-1-(1h-Indol-3-Yl)-3-{[5-(3-Methyl-1h-Indazol-5-Yl)pyridin-3-Yl]oxy}propan-2-Amine; (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan-2-amine; (S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine; (S)-1-(5-(3-Methyl-1H-indazol-5-yl)pyridin-3-yloxy)-3-(1H-indol-3-yl)propan-2-amine

CAS No.: 552325-16-3

Compound CID: 10172943

Formula: C₂₄H₂₃N₅

Formula Weight: 397.47

Specification

Targets&IC50: Chk1: 2.3 μM (ki); CK2: 2.4 μM (ki); c-Kit: 1.2 μM (ki); ERK2: 340 nM (ki); Akt3: 160 pM (ki); PKCδ: 33 nM (ki); PKCγ: 24 nM (ki); PKA: 6.3 nM (ki); CDK2: 24 nM (ki); MAPK-AP2: 3.3 μM (ki); KDR: 3.1 μM (ki); RSK2: 11 nM (ki); GSK-3β: 41 nM (ki); Akt1: 160 pM (ki); Akt2: 160 pM (ki); Src: 2.6 μM (ki)

Relative Density: 1.307 g/cm³

Stability: 3 years in powder form.

Storage: Storage at -20°C.

Applications: A-443654 can be used in oncology research to investigate the pan-inhibition of AKT and its impact on cell cycle progression.

Library Information

Target: PKA; Src; Akt; PKC; Chk; Casein kinase; MAPK; FLT; GSK-3; VEGFR; ERK; S6 Kinase; CDK

Receptor: Akt1; Akt2; Akt3; CDK2; Chk1; CK2; ERK2; Flt1; GSK-3β; KDR; MAPK; PKA; PKCγ; PKCδ; RSK2; SRC

Pathways: Metabolism; Cell cycle/Checkpoint; Stem cell regulation; Angiogenesis; PI3K/Akt/mTOR signaling; Chromatin/Epigenetic; Cytoskeletal signaling; MAPK; Tyrosine kinase/adaptors

Plate Number: AOCL-11

Plate Location: c5

Empty Location: a1-h1; a12-h12

Container: 96-well plate

Formulation: 10mM DMSO

DMSO Max Solubility: 150 mg/mL; 377.39 mM

Related Products

Inquiry

Inquiry Basket

Delete selected Check Out